Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This is a phase II study of OBP-301 with pembrolizumab in advanced gastric and
gastroesophageal junction adenocarcinoma that has progressed on at least 2 lines of prior
therapy for advanced disease.